| Autor: |
Ferrara M; Department of Obstetrics and Gynecology, Cannizzaro Hospital, University of Enna 'Kore', 94100 Enna, Italy., Pecorino B; Department of Obstetrics and Gynecology, Cannizzaro Hospital, University of Enna 'Kore', 94100 Enna, Italy., D'Agate MG; Department of Obstetrics and Gynecology, Cannizzaro Hospital, University of Enna 'Kore', 94100 Enna, Italy., Angelico G; Department of Anatomic Pathology and Histology, Cannizzaro Hospital, 95100 Catania, Italy., Capoluongo ED; Department of Clinical Pathology and Genomics, Cannizzaro Hospital, 95100 Catania, Italy., Malapelle U; Department of Public Health, University of Naples Federico II, 80126 Naples, Italy., Pepe F; Department of Public Health, University of Naples Federico II, 80126 Naples, Italy., Scollo P; Department of Obstetrics and Gynecology, Cannizzaro Hospital, University of Enna 'Kore', 94100 Enna, Italy., Mereu L; Department of Obstetrics and Gynecology, Policlinico G Rodolico, CHIRMED, University of Catania, 95124 Catania, Italy. |
| Abstrakt: |
Uterine tumors resembling ovarian sex-cord tumors (UTROSCT) are thought to develop from pluripotent uterine mesenchymal cells or endometrial stromal cells with secondary sex-cord differentiation. The patient was a 73-year-old postmenopausal woman who had abnormal vaginal bleeding, and she underwent a laparoscopic hysterectomy with bilateral salpingo-oophorectomy. The diagnosis was a case of UTROSCT. A scoping review of the UTROSCT case report present in the literature has been conducted, and 63 articles were found, of which 45 were considered for the 66 clinical cases examined. At the time of diagnosis, six metastatic localizations were found in 59 patients undergoing demolitive surgery (10.2%). Recurrences were diagnosed in 13/59 (22%) patients with multiple locations. A molecular study was performed in 18/66 cases (27.3%) and genetic alterations were found in 10/18 (55.6%) patients. UTROSCTs are considered rare uterine tumors, typically with a favorable prognosis, and are generally considered to have a good prognosis. But, from the review done, they may already manifest themselves at advanced stages, with the possibility of recurrences even at a distance. It would, therefore, be important to be able to define the most aggressive forms and, perhaps, molecular investigation with sequencing could help identify patients most at risk. |
